 Study participants who meet eligibility criteria will be randomized to one of two treatment sequences i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21. Randomization will be stratified by whether the study participant received prior docetaxel treatment. 